What is SkinJect?
SkinJect is a development-stage biotechnology company focused on revolutionizing dermatological treatments. Its core innovation is a novel dissolvable microneedle patch designed for the treatment of basal and squamous cell skin cancer. This technology addresses a critical unmet clinical need by offering a less invasive and potentially less painful alternative to existing therapies, with the aim of reducing cancer recurrence rates. Given the high prevalence of these skin cancers in the American population, SkinJect's product targets a substantial patient demographic, particularly those diagnosed with basal cell carcinoma, the most common form of skin cancer. The company is actively advancing its proprietary technology and pursuing regulatory clearance for market entry in a competitive landscape.
How much funding has SkinJect raised?
SkinJect has raised a total of $1.5M across 1 funding round:
Unspecified
$1.5M
Unspecified (2021): $1.5M, investors not publicly disclosed
What's next for SkinJect?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for SkinJect. This capital infusion is expected to accelerate the company's path toward commercialization, likely supporting further clinical trials, manufacturing scale-up, and the acquisition of necessary regulatory approvals. The strategic nature of the recent financing suggests potential partnerships or synergistic collaborations that could enhance market penetration and adoption of its novel microneedle patch technology. SkinJect's focus on a significant unmet need in dermatology positions it for considerable growth as it moves towards bringing its less invasive treatment option to patients.
See full SkinJect company page
